Inceptua Early Access (a business unit of the Inceptua Group), and Sentynl Therapeutics Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases today announced that they have entered into a partnership to make Sentynl’s Nulibry available via an Early Access Program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A.
December 28 2020, Elevar Therapeutics, Inc, a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that it has entered into an exclusive agreement with Inceptua Group for the distribution and commercialization of Apealea® (paclitaxel micellar) in Europe.
December 28 2020, Elevar Therapeutics, Inc, a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that it has entered into an exclusive agreement with Inceptua Group for the distribution and commercialization of Apealea® (paclitaxel micellar) in Europe.